Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director · Former EVP, CFO, & Director | November 15, 2023 | November 17, 2023 |
| Altimmune, Inc.ALT · Entity 5349 | Chief Financial Officer | October 01, 2026 | October 05, 2026 |
| Atai Beckley N.V.ATAI · Entity 72536 | Chief Financial Officer | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date November 15, 2023 · Filed November 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55 |
Reported balance
After 2023-11-15 transaction · row 1
1 source rowRow 1 · 2023-11-15 · Sale · Disposed 50,000 · Balance 55 |
Altimmune, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 49,927 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 14,475 · Balance 54,306 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Row 2 · 2026-10-01 · Tax withholding · Disposed 4,379 · Balance 49,927 F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 43,425 |
Reported balance
After 2026-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Disposed 14,475 · Balance 43,425 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Atai Beckley N.V.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2032-03-01 | Direct | 228,000 |
Reported balance
After 2022-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-02 · Grant · Acquired 228,000 · Balance 228,000 F1: The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eloxx Pharmaceuticals, Inc.
Report date March 15, 2020 · Filed March 16, 2020
Section 16 reporting ended · disclosed 2020-03-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,431 |
Ending reported balance
After 2020-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-15 · Exercise / conversion · Acquired 3,750 · Balance 11,517 F1: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. Row 2 · 2020-03-15 · Tax withholding · Disposed 1,086 · Balance 10,431 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-15 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F4: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited.
Zyla Life Sciences
Report date January 31, 2019 · Filed February 05, 2019
Section 16 reporting ended · disclosed 2019-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2024-02-04 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-31 · Disposition to issuer · Disposed 2,083 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2024-06-09 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-31 · Disposition to issuer · Disposed 667 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2024-09-30 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-31 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.08 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-31 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-31 · Disposition to issuer · Disposed 29,666 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-31 · Disposition to issuer · Disposed 58,133 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-05-14 | Direct | 0 |
Reported balance
After 2019-01-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.70 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 3 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-09-30 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 667 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires 2024-06-09 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 01:10 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,083 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001179110-19-001267 · edgar.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2024-02-04 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:49 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000111 · form4-01312019_040123.xml · derivative · entry 2 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. F4 · derivative.expiration_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:49 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 60,000 | $0.00 Strike: $11.53 | $0.00 |
DisclosureSEC source: 0001415889-19-000111 · form4-01312019_040123.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-30 F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:02 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-18-005994 · s111128_form4.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:20 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-006813 · edgar.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: These options to purchase shares of common stock vest 100% on the day prior to the date of the Corporation's annual meeting of stockholders to be held in 2019 subject to the director's continued service through the vesting date. Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 21:11 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 4,500 | $8.56 | $38,520.00 |
DisclosureSEC source: 0001209191-18-021643 · doc4.xml · nonDerivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 19:50 UTC | Eloxx Pharmaceuticals, Inc. SVON · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 399,266 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001144204-17-065040 · tv482001_4.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,266 Underlying: Common Stock · 399,266 shares Expires 2027-12-20 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| December 20, 2017 Filed Feb 23, 2018 21:17 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 399,266 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-18-012960 · doc4a.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,266 Underlying: Common Stock · 399,266 shares Expires 2027-12-19 F1 · derivative.exercise_price: The initial Form 4 filed on December 22, 2017, by the Reporting Person inadvertently overstated the exercise price of the option. F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:34 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 58,133 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001179110-17-008915 · edgar.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,133 Underlying: Common Stock · 58,133 shares Expires 2027-06-08 F1 · derivative.exercise_date: These options to purchase shares of common stock vest 100% on the day prior to the date of the Corporation's annual meeting of stockholders to be held in 2018 subject to the director's continued service through the vesting date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 17:55 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 54,949 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001615774-17-002749 · s106366_form4.xml · derivative · entry 1 WEAVER GREGORY L · CIK 0001251779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,917 Underlying: Common Stock · 54,949 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.